Sort by
Refine Your Search
-
following treatment. NEWDAY-ABC is a hybrid intervention-implementation trial that will be carried out at four sites across Yorkshire and Greater Manchester. The parallel process evaluation will assess
-
ganglia cultures to benchmark the newly developed iPSC derived organoid model systems. This will include processing of human DRG and nerve roots with subsequent cellular and molecular analyses looking
-
mechanisms in parallel, ensuring accelerated assessment of existing and new therapies. Improving our understanding of the cellular basis of disease will help bridge the gap between drug development and trial
-
of multiple medicines across cellular mechanisms in parallel, ensuring accelerated assessment of existing and new therapies. Improving our understanding of the cellular basis of disease will help bridge the gap
-
bioinformatics. The role will be responsible for developing and characterising human dorsal root ganglia cultures to benchmark the newly developed iPSC derived organoid model systems. This will include processing
-
parallel, the Institute is developing state-of-the-art methods that integrate living tissues with synthetic scaffolds to model and repair organs. These efforts converge across three interrelated programmes
-
institute is expanding this approach to detect a wider range of biological molecules, including volatiles in human breath. In parallel, the Institute is developing state-of-the-art methods that integrate